White matter lesions and the cholinergic deficit in aging and mild cognitive impairment

Nils Richter1, Anne Michel2, Oezguer A Onur3

  • 1Department of Neurology, University Hospital Cologne, Cologne, Germany; Cognitive Neuroscience, Institute of Neuroscience and Medicine (INM-3), Research Center Jülich, Jülich, Germany; Max Planck Institute for Metabolism Research, Cologne, Germany.

Neurobiology of Aging
|February 17, 2017
PubMed

Insights

White matter lesions (WMLs) in Alzheimer's disease (AD) impact memory by affecting the cholinergic system. Periventricular WMLs specifically correlate with reduced acetylcholinesterase (AChE) activity, which mediates memory decline in mild cognitive impairment (MCI).

Area of Science:

  • Neuroscience
  • Neurology
  • Radiology

Background:

  • Alzheimer's disease (AD) is characterized by white matter lesions (WMLs) and cholinergic deficits, both linked to cognitive decline.
  • WMLs, particularly in the periventricular regions, are associated with increased risk of dementia progression in mild cognitive impairment (MCI).
  • Memory impairment in AD is partly attributed to a deficit in the cholinergic system.

Purpose of the Study:

  • To investigate the relationship between WML load, cerebral acetylcholinesterase (AChE) activity, and memory performance in MCI due to AD.
  • To determine if WML distribution influences cholinergic function and memory deficits.
  • To compare the predictive power of AChE activity versus WML load for memory function.

Main Methods:

  • Assessed WML load using the Scheltens scale in 17 MCI patients and 18 controls.
  • Measured cerebral AChE activity via [11C]N-methyl-4-piperidyl acetate positron emission tomography (PET).
  • Evaluated neuropsychological performance, focusing on memory function.

Main Results:

  • Periventricular WML load, but not nonperiventricular, negatively correlated with AChE activity in both groups.
  • Memory performance was associated with both periventricular and total WML load.
  • AChE activity was a stronger predictor of memory function than WML load, gray matter atrophy, or age.
  • The impact of WML load on memory was fully mediated by AChE activity.

Conclusions:

  • The distribution of WMLs influences their contribution to cholinergic system dysfunction in MCI due to AD.
  • AChE activity plays a crucial role in mediating the relationship between WMLs and memory deficits.
  • Further pharmacologic studies are needed to explore the influence of WML distribution on response to cholinergic treatments.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
633
Role of Neurotransmitters in Memory01:23

Role of Neurotransmitters in Memory

Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
 Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
2.8K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
766
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
1.0K